Form 4: Amicus Therapeutics CEO Bradley Campbell Reports Stock Transactions

Amicus Therapeutics' CEO, Bradley Campbell, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 1, 2024, Bradley L Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 7,500 shares at $8.61 and 8,333 shares at $12.28.
• He then sold 15,833 shares of common stock at a weighted average price of $13.1382, with prices ranging from $12.95 to $13.55.
• Following these transactions, Campbell directly owns 871,219 shares of Amicus Therapeutics common stock.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on August 23, 2023.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned strategy, but the sale of shares could raise minor concerns.

Positives

• The CEO's transactions are part of a pre-arranged trading plan, suggesting they are not based on immediate insider knowledge.
• The CEO still holds a significant number of shares (871,219), indicating continued alignment with the company's success.

Negatives

• The sale of shares by the CEO, even under a pre-arranged plan, could be perceived negatively by some investors.

Risks

• While the transactions are under a 10b5-1 plan, continued selling by the CEO could create negative market sentiment.
• The price range of the stock sale ($12.95 to $13.55) could indicate potential price volatility.

Future Outlook

The document does not contain specific forward-looking statements, but the CEO's continued stock ownership suggests a long-term commitment to the company.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and are closely watched by investors for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options, and it's common for executives to exercise these options and sell shares for personal financial management.
• The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.
• Comparing Campbell's transactions to those of executives at similar-sized biotech companies (e.g., BioMarin, Sarepta Therapeutics) would provide context on the scale and frequency of such transactions.

Stakeholder Impact

• Shareholders may react to the CEO's stock sale, although the pre-arranged plan mitigates potential concerns.
• Employees may be indirectly affected by any market reaction to the CEO's transactions.

Key Dates